More than two-thirds of cancer patients who were prescribed medical marijuana to combat pain are reportedly satisfied with the treatment, according to a comprehensive study conducted for the first time in Israel.

The study – conducted recently at Sheba Medical Center, Tel Hashomer, in conjunction with the Israel Cancer Association – involved 264 cancer patients who were treated with medical marijuana for a full year.

Some 61 percent of the respondents reported a significant improvement in their quality of life as a result of the medical marijuana, while 56 percent noted an improvement in their ability to manage pain. In general, 67 percent were in favor of the treatment, while 65 percent said they would recommend it to other patients.

The findings were presented earlier this month at an Israeli Oncologists Union conference in Eilat. The study was led by Dr. Ido Wolf, the director of oncology at the Sheba Cancer Center, with the assistance of researchers Yasmin Leshem, Damien Urbach, Adato Berliz, Tamar Ben Ephraim and Meital Gerty.

According to the study, the most common types of cancer for which medical marijuana is prescribed are lung cancer (21 percent ), breast cancer (12 percent ) and pancreatic cancer (10 percent ).

Researchers found that an average of 325 days passed between the time that patients were diagnosed with cancer and the time that they submitted permit requests to grow or possess medical marijuana. About 81 percent of those requests cited pain resulting from the illness. Some 8 percent of patients requested medical marijuana to combat nausea, while another 8 percent complained of weakness.

For more, go to Haaretz.com

I’m personally matching all gifts to the Forward, up to $36,000. Can I match your gift now?

Hello, fellow Forward reader! I’m Joel Brown, a Forward reader and supporter for more than 15 years, and currently the chair of the board of directors.

I’m an avid Forward reader because it ticks so many of my essential boxes: excellent journalism, Jewish focus and diverse viewpoints. In today’s political climate, what I most appreciate is the Forward’s independence — made possible by the generosity of its membership.

The Forward is committed to bringing you unbiased, nuanced Jewish news. From my position as board chair, I see an exciting future as we expand our position as the definitive independent voice of contemporary American Judaism.

That’s why I’m paying it Forward. I’ve offered a $36,000 matching gift as an investment in the Forward’s newsroom, and I hope you’ll take me up on my offer to double your gift.

Don't just read the Forward - invest in it. Will you support our work today?

— Joel Brown, Forward board chair

Support our mission to tell the Jewish story fully and fairly.

$120 $180 $360 OTHER AMOUNT